Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Nehal J. Lakhani, Amita Patnaik, John B. Liao, John William Moroney, David S. Miller, Gini F. Fleming, Matt Axt, Yan V. Wang, Balaji Agoram, Jens-Peter Volkmer, Roy Maute, Andreas Schroeder, Isagani Chico, Mark Chao, Chris H.M. Takimoto, Kathleen N. Moore | ||||||||||||
Title | A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients. | ||||||||||||
|
|||||||||||||
URL | https://meetinglibrary.asco.org/record/183103/abstract | ||||||||||||
Abstract Text | J Clin Oncol 38, 2020 (suppl 5; abstr 18) |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | ovarian cancer | predicted - sensitive | Atezolizumab + Hu5F9-G4 | Case Reports/Case Series | Actionable | In a Phase Ib trial, Tecentriq (atezolizumab) and Magrolimab (Hu5F9-G4) combination therapy resulted in tumor shrinkage in a patient with platinum-resistant ovarian cancer with tumor CD274 (PD-L1) expression (J Clin Oncol 38, 2020 (suppl 5; abstr 18); NCT03558139). | detail... |